Abon Pharms Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ABON PHARMS LLC
ABON PHARMS LLC has five approved drugs.
Drugs and US Patents for Abon Pharms Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abon Pharms Llc | SUCRALFATE | sucralfate | SUSPENSION;ORAL | 216726-001 | Mar 21, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abon Pharms Llc | ERYTHROMYCIN | erythromycin | TABLET;ORAL | 219691-001 | Sep 23, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abon Pharms Llc | GABAPENTIN | gabapentin | TABLET;ORAL | 203643-001 | Sep 9, 2024 | AB2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

